Insight

Jun 30, 2024, 14:51

Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer

Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about a recent paper by Myriam Chalabi et al. titled “Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer” published in The New England Journal of Medicine:

Sergio Cifuentes commented on X sharing this paper:

“Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer: 98% timely surgery, 95% major pathological response, 0 recurrences in 26 months.”

Source: Sergio Cifuentes/X

Anja Van Lent Brechtje Grotenhuis cancer Cecile Grootscholten CENEIT México dMMR dMMR colon cancer Eduard Hendriks Emile Voest Geerard Beets Inge Huibregtse ipilimumab Jacobus Burger John Haanen José van den Berg June Rogers Colon Cancer Research Fund. Koert Kuhlmann Lodewyk Wessels Monique Van Leerdam Myriam Chalabi Neoadjuvant nivolumab plus ipilimumab Nikè Büller nivolumab OncoDaily Oncology Pedro Batista Tan Petur Snaebjornsson Regina Beets-Tan Sara Balduzzi Sergio Cifuentes Simone Dokter Steven Oosterling Tjeerd Aukema Ton Schumacher Yara Verschoor

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research